Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral | Zendy

Leen Delang | Zendy; Nidya Alexandra Segura | Zendy; Ali Taş | Zendy; Gilles Quérat | Zendy; Boris Pastorino | Zendy; Matheus Froeyen | Zendy; Kai Dallmeier | Zendy; Dirk Jochmans | Zendy; Piet Herdewijn | Zendy; Felio J. Bello | Zendy; Eric J. Snijder | Zendy; Xavier de Lamballerie | Zendy; B Martina | Zendy; Johan Neyts | Zendy; Martijn J. van Hemert | Zendy; Pieter Leyssen | Zendy

Open Access

Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral

Author(s) -

Leen Delang,

Nidya Alexandra Segura,

Ali Taş,

Gilles Quérat,

Boris Pastorino,

Matheus Froeyen,

Kai Dallmeier,

Dirk Jochmans,

Piet Herdewijn,

Felio J. Bello,

Eric J. Snijder,

Xavier de Lamballerie,

B Martina,

Johan Neyts,

Martijn J. van Hemert,

Pieter Leyssen

Publication year - 2014

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dku209

Subject(s) - favipiravir , virology , virus , biology , chikungunya , viral replication , antiviral drug , resistance mutation , rna dependent rna polymerase , clone (java method) , rna , genetics , gene , reverse transcriptase , medicine , infectious disease (medical specialty) , disease , pathology , covid-19

T-705, also known as favipiravir, is a small-molecule inhibitor that is currently in clinical development for the treatment of influenza virus infections. This molecule also inhibits the replication of a broad spectrum of other RNA viruses. The objective of this study was to investigate the antiviral effect of favipiravir on chikungunya virus (CHIKV) replication and to contribute to unravelling the molecular mechanism of action against this virus.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research